Traders should monitor for follow-up announcements post-AACR presentation, including potential partnership talks or research expansions. This proof-of-concept strengthens Evaxion’s platform narrative, which may re-rate the stock if commercial interest materializes.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 17 $4.45entry
- T+1 · 7mo ago +0.90%α +1.09% · $4.49
- T+5 · 7mo ago −9.44%α −9.99% · $4.03
- T+20 · 6mo ago −7.42%α −12.79% · $4.12
- T+60 · 4mo ago −31.91%α −38.05% · $3.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced new data from a collaboration with Duke University showing its AI-Immunology™ platform can identify endogenous retrovirus (ERV)-derived antigens for use in personalized vaccines for glioblastoma, a deadly brain cancer with limited treatment options. The findings, to be presented at AACR 2026, demonstrate a novel antigen source that could improve vaccine efficacy in low mutational burden cancers.
Key Facts
- AI-Immunology™ platform identified ERV-derived antigens in glioblastoma tumor samples, a novel target source absent in normal tissue.
- Data shows feasibility of including both ERV antigens and neoantigens in personalized vaccines for most glioblastoma patients.
- Immunologic responses to ERV antigens were experimentally confirmed, supporting clinical potential.
- Results to be presented at AACR Annual Meeting on April 22, 2026, increasing scientific visibility.
- Glioblastoma has low mutational burden and few neoantigens, making this new antigen source highly significant.
Financial Impact
Non-dilutive scientific validation with potential to increase partnership and licensing interest; no immediate revenue impact but enhances platform valuation.
Risk Factors
- Clinical application remains preclinical; no guarantee of therapeutic success in humans.
- High market expectations could lead to sell-off if AACR data underwhelms or lacks robustness.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276449 |
Track record
50 reports on EVAX
6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers